SAN FRANCISCO — The 62nd Annual Scientific Session of the American College of Cardiology (ACC; Bethesda, Maryland) kicked off here early on Saturday morning with a new and surprising turn in a series of unusual events that have surrounded the Prospective Randomized Evaluation of the Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy (PREVAIL) trial. Read More
